Category: Market News

  • Gold rebounds as Trump signals headway in Iran negotiations, but metal still set for weekly decline

    Gold rebounds as Trump signals headway in Iran negotiations, but metal still set for weekly decline

    Gold prices advanced more than 2% during Asian trading on Friday, supported by a softer U.S. dollar and signs that geopolitical tensions may be easing after Donald Trump indicated that talks with Iran were making progress.

    Spot gold rose 2.1% to $4,467.32 per ounce as of 02:41 ET (06:41 GMT), while U.S. gold futures climbed 1.1% to $4,457.6 per ounce.

    Even with Friday’s gain, bullion remained under pressure for the week after dropping nearly 3% in the previous session, leaving prices on track for a weekly decline of around 0.5%.

    Trump halts strikes on Iranian energy infrastructure

    President Trump said on Thursday that the United States would suspend attacks on Iran’s energy facilities for 10 days after a request from Tehran, adding that negotiations were “going very well.”

    The pause in military action reduced immediate demand for safe-haven assets, although it also weighed on the U.S. dollar, offering support to gold, which typically moves inversely to the greenback.

    The U.S. Dollar Index slipped 0.1% after posting gains for three straight days.

    Gold markets have experienced significant swings in recent weeks as the conflict in the Middle East disrupted the metal’s usual safe-haven behavior.

    Earlier this month, a surge in oil prices sparked by supply disruptions tied to the Iran conflict raised concerns about a potential rise in global inflation.

    Higher energy costs could keep inflation elevated and reinforce expectations that central banks will keep interest rates at higher levels for longer.

    Silver and platinum rally

    Oil prices edged lower on Friday and were on course for a weekly drop as diplomatic discussions aimed at reducing tensions gained momentum.

    However, lingering uncertainty over the direction of the conflict and mixed signals about efforts to end the fighting continued to leave investors cautious.

    Among other precious metals, silver climbed 2.6% to $68.75 per ounce, while platinum surged 3.5% to $1,901.60 per ounce.

    Benchmark copper futures on the London Metal Exchange increased 1% to $12,254.95 per ton, while U.S. copper futures rose 1.1% to $5.53 per pound.

  • Trump pushes back deadline for Iran energy strikes — key drivers for markets: Dow Jones, S&P, Nasdaq, Wall Street Futures

    Trump pushes back deadline for Iran energy strikes — key drivers for markets: Dow Jones, S&P, Nasdaq, Wall Street Futures

    U.S. equity futures were trading near unchanged levels on Friday after President Donald Trump said the United States would delay a deadline for potential strikes on Iranian energy infrastructure. Washington is demanding that Tehran reopen the Strait of Hormuz, and Trump said discussions with Iran are continuing even as violence in the Middle East persists. Oil prices extended their gains, while gold appeared headed for a weekly decline.

    Futures show little movement

    Futures tied to the main U.S. indexes edged modestly higher early Friday after Trump said Iran now has until April 6 to reopen the Strait of Hormuz or risk attacks on its power facilities.

    At 04:23 ET, Dow futures were up 27 points, or 0.1%. Futures linked to the S&P 500 gained 8 points, also around 0.1%, while Nasdaq 100 futures advanced 16 points, roughly 0.1%.

    Wall Street’s major benchmarks had fallen sharply in the previous session, recording one of their worst performances of the year so far. The decline came amid limited signs that diplomatic efforts to resolve the nearly month-long conflict involving U.S. and Israeli forces against Iran were making meaningful progress.

    Hostilities across the Middle East have continued, leaving the Strait of Hormuz effectively closed to tanker shipments and sustaining fears of additional attacks on crucial energy infrastructure in the region. Israel and Iran exchanged strikes again on Friday, while the Pentagon has reportedly been increasing its military presence in the area ahead of what some investors fear could become a U.S. ground operation in Iran.

    A report from the OECD released Thursday warned that the war could weaken the global economic outlook, noting that a surge in energy prices might trigger stronger inflationary pressures and weigh on economic expansion.

    Outside the geopolitical tensions, analysts at Vital Knowledge pointed to developments in the artificial intelligence industry, highlighting OpenAI’s decision to step away from some consumer-focused products. They suggested this may indicate that start-ups in the rapidly expanding AI sector are shifting their focus toward profitability and cash generation rather than simply building user bases.

    “[T]his could cause the tsunami of AI infrastructure spending to slow at the margin,” the analysts wrote in a note.

    Trump delays deadline for Iranian energy targets

    Despite other developments, markets remain primarily focused on the situation involving Iran, particularly Trump’s decision to extend the White House deadline for potential strikes on Iranian power facilities until April 6.

    In a message posted on Truth Social, Trump said the delay came at the request of the Iranian government and claimed that Tehran was engaged in “ongoing” discussions with Washington that are “going very well.” He dismissed reports suggesting otherwise as “erroneous.”

    Last weekend, Trump issued an ultimatum warning that U.S. forces would strike Iranian power plants if the Strait of Hormuz — a crucial route carrying roughly one-fifth of the world’s oil — was not reopened. He later indicated that any action would be postponed until Friday following what he described as “very strong” talks with Iranian officials.

    Iranian authorities, however, have publicly denied that negotiations with the United States are taking place.

    Some observers argue that both sides may be presenting incomplete accounts of events, leaving investors uncertain about the future direction of the conflict.

    Oil prices continue rising

    What remains clear is that tanker movements through the Strait of Hormuz are still heavily restricted and the threat of further attacks on energy facilities in the Persian Gulf remains.

    The disruption has created a major shock to global oil supply, limiting exports from one of the world’s most important energy-producing regions and affecting industries that rely on those imports.

    Brent crude — the global oil benchmark — has become a central indicator of the war’s economic impact. Prices have climbed far above levels seen before the conflict began and continued to move higher on Friday.

    The sustained rally has heightened concerns that higher energy costs could drive global inflation upward, potentially forcing central banks to reconsider raising interest rates even as economic growth slows.

    Gold set for weekly loss

    Gold prices rose on Friday but gave back part of their earlier gains following Trump’s announcement.

    By 05:03 ET, spot gold had increased 1.2% to $4,427.31 per ounce, while U.S. gold futures were up 1.1% at $4,456.01 per ounce.

    Even with Friday’s advance, bullion remained on course to decline around 1.4% over the week after slipping in the previous session.

    Persistently high energy costs could keep inflation elevated and strengthen expectations that central banks will keep borrowing costs higher for longer. Gold often struggles in such high-rate environments.

    Carnival results due

    On the corporate side, Carnival Corp. (NYSE:CCL) is scheduled to report earnings on Friday, potentially offering insight into how the conflict in the Middle East is affecting businesses.

    Analysts say the sharp increase in oil prices caused by the war is likely to raise fuel expenses for cruise operators such as Carnival.

    Cruise companies typically hedge against oil price volatility by using financial contracts that lock in fuel costs. However, analysts note that Carnival is the only major U.S. cruise line that does not currently hedge its fuel exposure, potentially leaving its earnings more vulnerable to the recent surge in energy prices.

    Shares of Carnival have fallen by more than 18% so far this year.

  • European shares steady as Trump delays deadline for Iran power plant strikes: DAX, CAC, FTSE100

    European shares steady as Trump delays deadline for Iran power plant strikes: DAX, CAC, FTSE100

    European equities traded largely flat on Friday while oil prices stayed elevated after U.S. President Donald Trump pushed back the deadline for potential air strikes on Iranian power facilities to April 6.

    At 08:02 GMT, the pan-European Stoxx 600 showed little movement, with Germany’s DAX and France’s CAC 40 also hovering near unchanged levels. The U.K.’s FTSE 100 edged up about 0.4%.

    In a social media post on Thursday, Trump said the extension was granted following a request from the Iranian government, which he claimed has been holding ongoing discussions with Washington. Iranian officials, however, have denied that negotiations with the United States are underway.

    The situation follows an ultimatum issued by Trump last week warning that Iran’s energy infrastructure could be targeted unless Tehran moved within 48 hours to reopen the Strait of Hormuz. On Monday, he extended that deadline to Friday.

    Despite the warning, tanker traffic through the Strait of Hormuz remains severely disrupted. The strategic waterway along Iran’s southern coastline carries roughly 20% of global oil shipments, and its closure has intensified pressure on the global economy, restricting key energy supplies and heightening fears of inflation driven by rising energy costs.

    There were few indications that a resolution to the conflict was close. The confrontation has persisted since joint U.S. and Israeli forces launched strikes on Iran in late February, and reports on Friday suggested that Israel and Iran had exchanged additional missile attacks.

    Diplomats from the Group of Seven are expected to meet in France, where Washington’s push for international assistance to reopen the Strait of Hormuz is likely to be a central topic. So far, those appeals have largely met resistance.

    Amid the geopolitical tension, oil prices remained firm as the volatile trading week drew toward its end. Brent crude futures for May delivery, the global benchmark, were last up 1.2% at $109.25 per barrel, recovering part of the losses seen earlier in the week and remaining well above levels recorded before the conflict began.

  • AstraZeneca shares rise after encouraging COPD trial results

    AstraZeneca shares rise after encouraging COPD trial results

    AstraZeneca PLC (LSE:AZN) shares climbed 2.8% on Friday after the company reported that its experimental therapy tozorakimab achieved the primary endpoint in two Phase III trials targeting chronic obstructive pulmonary disease (COPD).

    The pharmaceutical group released the findings from the OBERON and TITANIA studies on Thursday. The trials showed that tozorakimab significantly lowered the annualised rate of moderate-to-severe COPD flare-ups compared with placebo, both in the key group of former smokers and across the broader patient population.

    According to AstraZeneca, the treatment was generally well tolerated and demonstrated a favourable safety profile during the studies.

    Tozorakimab is a monoclonal antibody designed to target interleukin-33 (IL-33), blocking signalling from both the reduced and oxidised forms of the protein. The trials evaluated the therapy in patients who continued to experience COPD exacerbations despite receiving inhaled standard treatments. Participants were given either 300 mg of tozorakimab or a placebo every four weeks alongside standard care.

    COPD affects nearly 400 million people worldwide and ranks as the third leading cause of death globally. More than half of patients still suffer exacerbations even while receiving inhaled standard therapies, increasing their risk of serious cardiopulmonary complications and death.

    Across the two trials, 2,306 patients were enrolled regardless of their blood eosinophil levels, smoking history or stage of lung function impairment. Researchers assessed the annualised rate of moderate-to-severe COPD exacerbations over a 52-week treatment period.

    AstraZeneca said complete data from the OBERON and TITANIA trials will be presented at a forthcoming medical conference. Additional Phase III studies of tozorakimab in COPD—PROSPERO and MIRANDA—are currently underway. The therapy is also being evaluated in a Phase III trial for severe viral lower respiratory tract disease and in a Phase II study for asthma.

  • Pernod Ricard shares trim losses as investors assess merger talks

    Pernod Ricard shares trim losses as investors assess merger talks

    Pernod Ricard (EU:RI) shares trimmed earlier losses on Friday as investors reassessed reports that the French drinks group is in discussions about a potential combination with Jack Daniel’s producer Brown-Forman (NYSE:BF.A).

    The stock had dropped sharply in the previous session after Pernod Ricard (EU:RI) confirmed it was exploring a possible deal with the U.S.-based distiller. By 0744 GMT on Friday, however, the shares had recovered some ground, rising 3.2% to 61.86 euros.

    Analysts at Jefferies, J.P. Morgan and Bernstein suggested that a transaction could carry strategic logic, particularly at a time when the spirits industry is facing softer demand for alcoholic beverages and ongoing uncertainty linked to global trade tensions.

    In a note to clients, Jefferies said a merger could help revive momentum in a sector that has recently struggled to generate meaningful growth.

    Bernstein analysts also cautioned against reading too much into the sharp share-price reaction seen on Thursday. They argued the market’s moves implied a significant shift of value from Pernod Ricard to Brown-Forman and suggested no value would be created, assumptions they said could ultimately prove incorrect.

    However, the firm added that even if a deal were completed, it would not necessarily resolve the industry’s most immediate challenge: generating stronger revenue growth.

    On Thursday, Pernod Ricard shares finished the session down nearly 6% at 59.94 euros, while Brown-Forman gained 9% to close at $25.74.

    J.P. Morgan analysts noted that Pernod Ricard’s already stretched balance sheet could make a transaction of this scale difficult to execute. Nonetheless, they acknowledged the potential strategic benefits, including cost efficiencies and the ability to leverage each company’s distribution networks more effectively.

    Based on Thursday’s closing prices, Brown-Forman had a market value of close to $12 billion, while Pernod Ricard’s market capitalisation stood at roughly 15 billion euros (about $17 billion).

  • Seeing Machines lifts royalties and recurring revenue as vehicle installations top 4.8 million

    Seeing Machines lifts royalties and recurring revenue as vehicle installations top 4.8 million

    Seeing Machines (LSE:SEE) reported mixed results for the half year to 31 December 2025, with adjusted revenue falling 8% to US$23.4 million as income from OEM engineering services and licence agreements declined. However, the company recorded strong growth in recurring revenue streams, with annualised recurring revenue rising to US$14 million and Aftermarket sales increasing 18%, driven by continued demand for its Guardian driver monitoring safety system.

    Automotive production volumes incorporating the company’s technology increased sharply, rising 62% to around 1.1 million vehicles during the period. This expansion boosted higher-margin royalty revenue by 33% to US$8.4 million and helped narrow the adjusted EBITDA loss to US$13.7 million. Cash reserves stood at US$3.4 million at period end, although the balance was later supported by a post-period lump-sum royalty payment and the establishment of a new receivables financing facility.

    The company also strengthened its position in driver and occupant monitoring systems, with more than 4.8 million vehicles globally now using its technology. New programme wins in Europe and Japan, along with growing demand in the Aftermarket segment—including large fleet and autonomous vehicle orders in North America—added to commercial momentum. Seeing Machines is also developing new technologies such as 3D Cabin Perception Mapping and impairment detection tools aligned with emerging U.S. safety priorities, alongside its Future Mobility Group initiatives.

    These developments are expected to position the company to benefit from the implementation of Europe’s General Safety Regulation (GSR) requirements, which are anticipated to drive further royalty growth. Management continues to target positive adjusted EBITDA in the second half of FY2026 while also working to refinance a convertible note due in 2026.

    From an outlook perspective, the company still faces financial challenges, including ongoing losses and negative operating cash flow. Near-term technical indicators also appear weak. However, management commentary points to regulatory tailwinds, expanding automotive adoption and cost-control measures aimed at achieving cash-flow breakeven.

    More about Seeing Machines

    Seeing Machines is an Australia-based technology company specialising in AI-powered, vision-based monitoring systems designed to improve safety in transport. Its solutions track driver attention and cognitive state using computer vision, embedded processing and advanced optics. The technology is used across automotive, commercial fleet, off-road and aviation sectors, supplying driver and occupant monitoring systems to global automotive manufacturers, Tier 1 suppliers and fleet operators.

  • ImmuPharma advances P140 patent strategy while pursuing 2026 licensing deal

    ImmuPharma advances P140 patent strategy while pursuing 2026 licensing deal

    ImmuPharma (LSE:IMM) has reported progress in strengthening the intellectual property and scientific foundation of its P140 autoimmune technology platform. The company recently received a supportive first Combined Search and Examination Report for a UK patent application submitted in September 2025. As the next step, management plans to file under the Patent Cooperation Treaty to extend patent protection across major commercial markets, highlighting the strategic importance of P140 within its development pipeline.

    Further supporting the programme, a new study designed to stress test the associated diagnostic and reinforce statistical reliability delivered positive results that strengthen the patent position. In parallel, the company is preparing a scientific manuscript explaining the mechanism of action of P140 for submission to a peer-reviewed journal. ImmuPharma also continues to engage with potential partners, including meetings at the Bio Europe Spring conference, as it works toward securing a licensing agreement for P140 in 2026. Such a deal could play a significant role in shaping the company’s future revenue prospects and strategic positioning within the sector.

    From an outlook perspective, the company remains constrained by weak financial fundamentals, including minimal revenue, ongoing losses, continued cash burn and negative equity. Technical indicators present a mixed picture but show some modest support relative to the 200-day average. Valuation metrics remain challenging due to the lack of profitability and the absence of a dividend.

    More about ImmuPharma PLC

    ImmuPharma PLC is a UK-listed specialty biopharmaceutical company focused on the discovery and development of peptide-based therapies. Its research programmes target autoimmune conditions and anti-infective indications, positioning the company within a specialised segment of the biopharmaceutical industry focused on precision treatments for immune-related diseases.

  • Avacta launches £10m equity raise to support oncology pipeline development

    Avacta launches £10m equity raise to support oncology pipeline development

    Avacta Group plc (LSE:AVCT) has announced plans to raise approximately £10 million through a discounted equity placing and subscription involving around 15.9 million new shares priced at 63 pence each. Zeus Capital is acting as sole bookrunner for the transaction. The company expects the net proceeds to fund research and development activities as well as general working capital, extending its cash runway into early Q1 2027 and beyond the anticipated Phase 1a data readout for AVA6103.

    The capital raise is intended to support continued clinical progress across Avacta’s oncology pipeline. This includes Phase 1b expansion cohorts for faridoxorubicin (AVA6000) across multiple cancer indications and the planned initiation of dosing for AVA6103, a pre|CISION-based exatecan peptide drug conjugate. Management has indicated it intends to retain full ownership of AVA6103 at least until the initial Phase 1a data expected in late 2026. Participation by company directors in the subscription is seen as a signal of internal confidence and positions the group for potential future partnership discussions around its lead assets and next-generation candidate AVA6207.

    From an outlook perspective, Avacta continues to face financial pressures, reflected in weak profitability and bearish technical indicators. Although the company is making progress with its clinical programmes, funding constraints and the absence of major commercial partnerships remain key risks. Valuation metrics also appear challenging given negative earnings and the lack of a dividend.

    More about Avacta Group plc

    Avacta Group plc is a clinical-stage biopharmaceutical and life sciences company developing cancer therapies using its proprietary pre|CISION tumour-activated drug delivery platform. The technology supports the development of peptide drug conjugates designed to deliver highly potent cancer treatments directly within the tumour microenvironment, aiming to improve effectiveness while reducing systemic toxicity compared with conventional antibody drug conjugates.

  • 80 Mile’s Jameson stake valued at US$104m as Greenland Energy begins Nasdaq trading

    80 Mile’s Jameson stake valued at US$104m as Greenland Energy begins Nasdaq trading

    80 Mile Plc (LSE:80M) has announced that Pelican Acquisition Corporation has completed its acquisition of Greenland Exploration Limited, which has now started trading on Nasdaq as Greenland Energy Company under the ticker GLND. The listing consolidates the Jameson hydrocarbon project in East Greenland within a single U.S.-listed entity. Under the terms of an existing joint venture, GLND can earn up to a 70% interest in the project by funding the drilling of two exploration wells, leaving 80 Mile with a 30% stake. Based on Greenland Energy’s latest market capitalisation, that retained interest is valued at approximately US$104 million.

    The Jameson project spans around two million acres in East Greenland and has undergone extensive technical evaluation. An independent report by Sproule ERCE estimates gross unrisked recoverable prospective oil resources of 13.03 billion barrels (P10), with roughly 3.9 billion barrels potentially attributable to 80 Mile following full earn-in by GLND. Preparations for drilling are advancing, with Halliburton contracted for drilling services, heavy equipment mobilised and logistical arrangements already in place. The Nasdaq listing of Greenland Energy is expected to provide a dedicated capital markets platform to fund and carry out a maiden drilling programme targeted for the second half of 2026, which could significantly reshape 80 Mile’s exposure to one of the world’s largest undeveloped onshore basins.

    From an outlook perspective, the company’s financial profile remains challenged by the absence of revenue, widening losses and ongoing cash burn, which increases the risk of future funding needs and potential dilution despite relatively low debt levels. Technical indicators show strong upward momentum and a supportive longer-term trend, although overbought signals suggest some caution in the near term. Valuation remains difficult to assess given negative earnings and the lack of dividend data.

    More about 80 Mile Plc

    80 Mile Plc is an exploration and development company listed on AIM in London, the Frankfurt Stock Exchange and the U.S. OTC market. The group focuses on hydrocarbon and high-grade critical metal projects in Greenland, while also operating an industrial gas and biofuels business in Italy. This diversified portfolio provides exposure across hydrocarbons, base and precious metals, as well as sustainable fuel markets.

  • Chariot secures economic exposure to producing Angolan oil assets

    Chariot secures economic exposure to producing Angolan oil assets

    Chariot (LSE:CHAR) has arranged financing that will give it economic exposure to producing offshore oil assets in Angola by supporting Etu Energias’ acquisition of stakes in Blocks 14 and 14K. The company has provided a US$12 million deposit and related transaction costs to help fund Etu’s purchase of a 20% working interest in Block 14 and a 10% stake in Block 14K. The transaction is also supported by an acquisition financing facility from Shell Western Supply and Trading, which will be repaid through future oil offtake.

    The funding package fully supports the acquisition and positions Chariot to benefit from long-term production-linked cash flows equivalent to roughly 4,000 barrels of oil per day. At an assumed oil price of US$60 per barrel, the arrangement is estimated to represent a net asset value exceeding US$100 million. The deal represents a strategic step for Chariot as it moves into material production within Angola’s established offshore basin, leveraging existing infrastructure operated by Chevron. Completion of the transaction is expected in the second half of 2026, subject to regulatory approvals.

    From an outlook perspective, the company continues to face financial pressures, including ongoing losses and bearish technical indicators. However, strategic developments such as partnerships and the company’s expanding focus on renewable energy projects may provide potential for longer-term improvement. Valuation remains constrained by the company’s current lack of profitability.

    More about Chariot Limited

    Chariot Limited is an Africa-focused energy group with two main business areas: upstream oil and gas and renewable power development. Its oil and gas portfolio spans Angola, Morocco and Namibia, while its renewable energy division focuses on power generation and trading in South Africa as well as advancing power-to-mining and green hydrogen projects, including Project Nour in Mauritania.